Company / Return on Equity (ROE)
Seres Therapeutics, Inc. Return on Equity (ROE) History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-825.0%
FY2025
5-year range
-825.0% / -49.9%
FY2021-FY2025
Trend
-1554.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Seres Therapeutics, Inc. reports negative total equity of -825.0% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-825.0% in FY2025 with a 3-year CAGR of -774.0%.
Declined from -51.0% to -825.0% over the past 3 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -774.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 1554.4% year-over-year.
- Peak return on equity (roe) was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -825.0% | -1554.4% |
| FY2023 | -49.9% | +2.2% |
| FY2022 | -51.0% | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | -147.3% | -113.3% |
| FY2018 | -69.0% | -158.9% |
| FY2017 | -26.7% | - |
| FY2016 | - | - |
| FY2015 | - | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026